Telix Commences Phase III Clinical Trial of Prostate Cancer Therapy

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 7/30/2026

1. META
2. MSFT
3. FTNT
4. QCOM
5. ARM
6. SBUX
7. CVNA
8. TENB
9. SPY
10. CMG

Go back to Telix Commences Phase III Clinical Trial of Prostate Cancer Therapy
TRANS-LUX CORPORATION (NASDAQ: TLX) Delayed: 10.02 -0.08 (0.79%)
Previous Close $10.10    52 Week High $2.18 
Open $10.04    52 Week Low $0.30 
Day High $10.04    P/E N/A 
Day Low $9.94    EPS $-3.32 
Volume 31,834